Publications by authors named "Irene Caballero"
Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study.
Front Endocrinol (Lausanne)
November 2023
Article Synopsis
- Semaglutide is an effective treatment for glycemic control and weight loss in type 2 diabetes (T2D) patients, including those with chronic kidney disease (CKD), showing no significant safety concerns over a 12-month period.
- In a study comparing T2D patients with and without CKD, both groups experienced reduced HbA1c levels and weight loss, although non-CKD patients lost slightly more weight.
- CKD severity had minimal impact on treatment efficacy and safety, suggesting that semaglutide can be safely used in T2D patients with varying levels of kidney function.
Purpose: To extend a prior real-world analysis (DARWIN-T2D) of patients with type 2 diabetes initiating dapagliflozin in Italy, Greece, and Spain by evaluating changes in glycemic and extra-glycemic endpoints after initiation of dapagliflozin.
Patients And Methods: The association among demographic/clinical characteristics and the change in glycemic and extraglycemic effectiveness endpoints during the observation period was assayed using a mixed effects model.
Results: A total of 1438 (860 males; 59.
Background: This study aims to evaluate dapagliflozin in patients with type 2 diabetes (T2D) in clinical practice in Spain.
Methods: This is a retrospective study including adults with T2D under stable antidiabetic therapy, with either dapagliflozin or sitagliptin ≥6 months, before inclusion. Data about the effectiveness and safety of dapagliflozin are presented.
Weight reduction and glycemic control are key goals during Type 2 diabetes management. However, there are few country-specific, real-world data on cotransporter 2 inhibitors. DAPA-RWE was a retrospective, multicenter study comparing the efficacy of dapagliflozin versus sitagliptin in Type 2 diabetes patients in Spain.
View Article and Find Full Text PDF• Patients COVID19 new-onset psychiatric symptoms because treatments or virus itself.
View Article and Find Full Text PDF